^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Solid Tumor
    Drug:Bavencio (avelumab) (PD-L1 inhibitor) +
    ImmuFact (eftilagimod alpha) (APC activator, MHC II agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    1033P - The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours

    Published date:
    09/14/2020
    Excerpt:
    This is an investigator-initiated study with currently 4 St: i.t. (A) or i.p. IMP321 (B); s.c. IMP321 with SOC (C) or combined with avelumab (D)...The SD gastric cancer pt of St A with PFS of 3 mo had an OS of 28 mo with increase of PD-L1 in the immune cells from 20% at baseline (BL) to 30% (D29 + D71). 3 SD pts with gastric cancer showed high CD45, CD163 expression at BL (tissue)...Intratumoral and intraperitoneal IMP321 can be safely administered up to 30 mg with signals of clinical and cytokine activity.
    Trial ID:
    INSIGHT